Table 1.
Demographic characteristics of 3674 patients admitted to the hospital with confirmed COVID-19, and drugs administered to them during their entire hospitalization (Hospital das Clínicas, University of Sao Paulo, Brazil—30 March–30 August, 2020)
| Demographic data | N: 3674 |
|---|---|
| Female sex, n (%) | 1682 (46%) |
| Age (years) | |
| Mean (SD) | 58 (17.9) |
| Median (range) | 60 (13–101) |
| Days of hospital stay | |
| Mean (SD) | 14.6 (1.3) |
| Median (range) | 10.3 (1–153) |
| Admission directly to an ICU, n (%) | 1475 (40%) |
| Deaths | 1169 (32%) |
| Number of prescriptions evaluated | 821,532 |
|---|---|
| Drugs | N (%) |
| Anticoagulants | 3445 (94) |
| Antibiotics | 3300 (90) |
| Antipyretics | 3010 (82) |
| Proton pump inhibitor | 2556 (70) |
| Sedatives | 2002 (54) |
| Electrolytes | 1958 (53) |
| Furosemide | 1916 (52) |
| Insulin | 1700 (46) |
| IV corticosteroids | 1652 (45) |
| Vasoactive drugs | 1572 (43) |
| Antipsychotic | 1458 (40) |
| Bisacodyl | 1360 (37) |
| Neuromuscular blocking agents | 1278 (35) |
| Oral corticosteroids | 1215 (33) |
| Antiviral drugs | 1160 (32) |
| Ondansetron | 849 (23) |
| Metoclopramide | 819 (22) |
| Anticonvulsive drugs | 751(20) |
| Hydrochlorothiazide | 739 (20) |
| Statins | 728 (20) |
| Anti-hypertensive calcium channel blocker | 660 (18) |
| Acetylsalicylic acid | 660 (18) |
| Methadone | 629 (17) |
| Blood components | 622 (17) |
| Angiotensin-converting enzyme inhibitors | 519 (14) |
| Angiotensin receptor blockers | 508 (14) |
| Vitamins | 505 (14) |
| Atropine | 503 (14) |
| Salbutamol | 488 (13) |
| Scopolamine | 447 (12) |
| Amiodarone | 431 (12) |
| Dimethicone | 431 (12) |
| Anti-hypertensive beta-blocker | 399 (11) |
| Levothyroxine | 392 (11) |
| Anti-hypertensive vasodilator | 352 (10) |
| Ivermectin | 312 (8) |
| Hydroxychloroquine | 43 (1) |
| Tocilizumab | 3 (0.1) |
SD standard deviation, ICU intensive care unit, IV intravenous